Back to Search
Start Over
Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma.
- Source :
- OncoImmunology; 2024, Vol. 13 Issue 1, p1-14, 14p
- Publication Year :
- 2024
-
Abstract
- Pancreatic ductal adenocarcinoma (PDAC) is currently difficult to treat, even when therapies are combined with immune checkpoint blockade (ICB). A novel strategy for immunotherapy would be to maximize the therapeutic potential of oncolytic viruses (OVs), which have been proven to engage the regulation of tumor microenvironment (TME) and cause-specific T-cell responses. To boost tumor sensitivity to ICB therapy, this study aimed to investigate how glutathione peroxide 4 (GPX4)-loaded OVs affect CD8<superscript>+</superscript> T cells and repair the immunosuppressive environment. Here, we successfully constructed a novel recombinant oncolytic vaccinia virus (OVV) encoding the mouse GPX4 gene. We found the OVV-GPX4 effectively replicated in tumor cells and prompted the expression of GPX4 in T cells. Our research indicated that OVV-GPX4 could reshape the TME, rectify the depletion of CD8<superscript>+</superscript>T cells, and enhance the antitumor effects of ICB therapy. [ABSTRACT FROM AUTHOR]
- Subjects :
- VACCINIA
PANCREATIC duct
IMMUNE checkpoint proteins
T cells
TUMOR microenvironment
Subjects
Details
- Language :
- English
- ISSN :
- 21624011
- Volume :
- 13
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- OncoImmunology
- Publication Type :
- Academic Journal
- Accession number :
- 181277074
- Full Text :
- https://doi.org/10.1080/2162402X.2024.2322173